Predictors of atelectasis after pulmonary lobectomy

Abstract

Postlobectomy atelectasis is an important postoperative complication. Patients with COPD and those undergoing RUL are at higher risk of this complication. Although often isolated, PLA is associated with longer hospital stay.

Impact of Airflow Limitation on Comorbidities and Postoperative Complications in Patients Undergoing Thoracic Surgery: A Retrospective Observational Study

“…14,15) Stolz et al reported that patients with COPD and those undergoing right upper lobectomy are at higher risk of postlobectomy atelectasis. 14) In our study, regardless of the existence of underlying diseases, the presence of airflow limitation itself was an independent risk factor for postoperative respiratory failure and atelectasis, which appears to be in broad agreement with these reports.…”

Retrospective Analysis of Hundred Patients who had Undergone Lobectomy for Lung Cancer

“…(12) akciğer kanseri tanısı alan 412 olgulık retrospektif çalışmalarında % 56 skuamöz karsinom, % 27 adenokarsinom tespit etmiştir. Serimizde skuamöz karsinom 53 (% 53) olguda tespit edildi ve skuamöz karsinom ile mortalite arasında anlamlı iliş-ki saptanmadı.…”

“…'ya indirilmesi ile komplikasyon sıklığının belirgin azaldığını bildirmiştir. Stolz'un serisinde (12) ameliyat süresi 126±27 dk. olup, pulmoner komplikasyon insidansı % 19.5 olarak bulunmuştur.…”

“…(21) 767 olguluk serisinde % 1.6 BPF ve % 41.7 mortalite saptamıştır. Diğer bir seride % 23 kardiyovasküler komplikasyon, % 8.7 uzamış hava kaçağı, % 6.6 atelektazi, % 2.9 pnömoni ve % 0.7 mortalite tespit edilmiştir (12) . Uramoto ve ark.…”

Early Complications after Lung Resections at Patients Treated For Lung Cancer with and Without Neoadjuvant Hemiotheraphy

“…Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients [3][4][5]. In last time there were many studys to use neoadjuvant hemiotheraphy for IB, IIA and IIB stage also [6][7][8][9][10][11][12]. Many trials have shown that preoperative chemotherapy for lung cancer is feasible but associated with postoperative morbidity and mortality [3,11].…”